Fuel Your Discoveries

Quick Explanation Copied

Author review — Han Altae-Tran (concise)

Altae-Tran is a productive computational/experimental researcher whose work on RNA-guided nucleases, compact RNA editors, and computational methods has high impact (multiple Science/Nature/Nat Biotech papers) and broad citations across 2013–2025 and Nature/Cell/NatBiotech articles

Long Explanation

Author Review: Han Altae-Tran — Evidence-based critique & visualization

Visual summary (citations & output over time)

Plot: cited-by counts per calendar year from OpenAlex summary (counts_by_year provided in author metadata).

Core evidence & representative high-impact works

High-impact first/senior-authored contributions to discovery of programmable RNA-guided endonucleases in widespread transposons (Science 2021), with experimental validation and evolutionary analysis
Author in Nature 2023 describing Fanzor — a eukaryotic programmable RNA-guided endonuclease — demonstrating cross-domain discoveries and experimental structural/functional work
Multiple contributions to compact RNA editors and CRISPR-related tool development in high-profile journals (Nat Biotech 2021; Cell 2021) indicating translational and methodological breadth

Author metrics (provided sources)

Microsoft Academic/semantic scholar style summary provided: h-index ≈ 17, total citations ≈ 1,766, paper count ≈ 25 (paper list provided).

OpenAlex record (aggregated): works_count = 38, cited_by_count = 4,434, h_index = 22 (counts_by_year shown in plot above) — indicating broader coverage in OpenAlex aggregation.

Note: different indexing sources (author-supplied list vs OpenAlex) yield different totals; OpenAlex aggregates more works and citations, raising h-index and cited_by_count compared with earlier snapshot.

Scientific strengths

High-impact, field-changing contributions (Science/Nature/Nat Biotech/Cell coauthorship and lead authorship) showing discovery + experimental validation in molecular biology and computational genomics
Interdisciplinary skillset — computational discovery, structural biology collaborations, and molecular tool engineering (e.g., Fanzor, Cas13, compact editors).
Rapid, sustained productivity across 2013–2025 with multiple widely-cited items (OpenAlex: works_count 38; cited_by_count 4,434) suggesting influence and robust citation footprint

Potential limitations & blindspots

Authorship mix: many high-impact items are multi-author collaborations; disentangling individual contribution across computational, experimental, and conceptual roles sometimes requires reading author contribution statements in each paper.
Translational maturity: several discoveries (Fanzor, compact editors, TnpB-based systems) are early-stage tool discoveries; broad in vivo safety, target range, and off-target profiling remain to be exhaustively characterized (common limitation for new nuclease tools)
Indexing/citation variance: differences between provided paper list and OpenAlex totals highlight the usual bibliometric uncertainty (database coverage, preprints, and name disambiguation affect h-index and citation totals).

Biases & sources of error to consider in judging the author

Publication bias toward positive/novel tool papers (common across genomics/CRISPR literature) — important to check negative/failed experiments or replication attempts where available.
Collaborative network effects: coauthorship with established groups (e.g., Broad, McGovern) can amplify visibility — separate scientific novelty from sociological citation amplification by reading methods and direct contributions.
Indexing heterogeneity (OpenAlex vs other indices) — reliance on one bibliometric source can misestimate impact; use multiple sources for robust assessment.

Conclusions (evidence-weighted)

Altae-Tran is an active, high-impact researcher bridging computational genomics and experimental molecular biology with multiple well-cited discoveries (TnpB/IS200 discovery, Fanzor, compact editors). Evidence shows strong novelty and interdisciplinary strength, with the normal caveats about early-stage tool maturation and bibliometric variability

What would change this assessment: large-scale independent replication showing poor nuclease specificity or failure to reproduce biochemical results would lower novelty/impact; conversely, robust in vivo demonstrations and tool development would strengthen translational impact.

Representative citations used in this review

Feedback:

Updated: January 28, 2026

BGPT Author Review

Scientific Quality

80%

Altae-Tran demonstrates high scientific capability: first/senior authorship on foundational genomic/biochemical discoveries (TnpB, Fanzor), strong interdisciplinary integration (computational genomics + experiments), and a robust citation footprint; minor deductions reflect bibliometric uncertainty and the early translational state of several tool-discovery papers.

Communication Quality

80%

Papers are published in top-tier journals with clear methods and substantial supporting data; exposition and collaborative clarity are generally strong, though some large multi-author works require reading author-contribution details to allocate credit precisely.

Author Novelty

90%

Contributions (discovering new classes of RNA-guided nucleases and eukaryotic Fanzor, compact RNA editors) are novel within CRISPR/evolutionary genomics space; novelty is high because these findings open new mechanistic and tool-development directions.

Scientific Rigor

80%

Work combines genome-scale computational searches, phylogenetics, structural biology, and biochemical validation — methods and controls are generally appropriate and detailed; some claims (tool readiness, broad specificity) require further extensive benchmarking and replication.

Key Insight

Discovering transposon-encoded RNA-guided nucleases reframes CRISPR evolution and suggests compact nuclease tool families that may be engineered for minimal-delivery therapeutic editing.

Keep Exploring

Which specific figures/data in Altae-Tran's key papers (Science 2021, Nature 2023) most critically support claimed activities and how reproducible are those assays?

Can we reanalyze raw off-target sequencing data from compact editor papers to quantify specificity and compare across nuclease families?

Analysis Wizard

Parsing OpenAlex counts_by_year and plotting citation/time curves to quantify citation trends and compute an approximate per-paper mean citation; useful for bibliometric trend analysis.

Hypothesis Graveyard

Hypothesis: TnpB systems are functionally equivalent to Cas9 across eukaryotes — rejected because current data show limited biochemical characterization and domain differences reducing direct equivalence.

Hypothesis: High citation counts guarantee translational readiness — unsound because citation reflects interest and novelty, not mature safety/efficacy validation.

Potential Experiments

Systematic in vitro off-target profiling: compare representative TnpB, Fanzor, and small Cas13 variants across standardized DNA/RNA libraries (k-mer randomized targets) to quantify specificity, mismatch tolerance, and cleavage kinetics; this directly tests tool readiness.

In vivo delivery/specificity head-to-head: package representative compact editors into identical AAV or LNP systems, deliver to the same cell/tissue types in parallel, and measure on/off-target edits by unbiased genome-wide assays (GUIDE-seq/CIRCLE-seq) to evaluate translational potential.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I prioritize methodological evidence and citation patterns from aggregated databases; I may underweight non-indexed contributions like software or internal datasets.

Get Ahead With Science Insights

Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.

Assess an author's data and outputs

See the raw experimental evidence behind an author's publications and reproducibility signals.